ArticleJournal of clinical laboratory analysis2020
Epidemiology and molecular characteristics of the type VI secretion system in Klebsiella pneumoniae isolated from bloodstream infections.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Succinate-driven virulence enhancement in hypervirulentMicrobiology spectrum · 2026Article
- Piecing together the puzzle: current knowledge and open questions about the Klebsiella pneumoniae type VI secretion system (T6SS).Memorias do Instituto Oswaldo Cruz · 2026Review
- Review
- Pathogenic Potential of Invasive Mucosa-Associated Klebsiella pneumoniae Isolates in Ulcerative Colitis: Characterization of Virulence Factors and Inflammatory Response.Immunity, inflammation and disease · 2025Article
- Multidrug-resistant hypervirulentFuture microbiology · 2025Review
- Article
- Identification of Antimicrobial Resistance Patterns, Type VI Secretion System, and Virulence Factors in Clinical Isolates ofInternational journal of microbiology · 2025Article
- Virulence Factors inIndian journal of microbiology · 2024Review
- Molecular Characteristics of Virulence Genes in Carbapenem-Resistant and Carbapenem-SensitiveInfection and drug resistance · 2024Article
- Type VI secretion system (T6SS) inIranian journal of microbiology · 2023Article
- Performance of next-generation sequencing for diagnosis of blood infections byFrontiers in cellular and infection microbiology · 2023Article
- The Biological and Regulatory Role of Type VI Secretion System ofInfection and drug resistance · 2023Review
- Molecular epidemiology and clinical characteristics of the type VI secretion system inFrontiers in microbiology · 2023Article
- Novel Virulence Factors DecipheringInternational journal of molecular sciences · 2022Article
- Role of Klebsiella pneumoniae Type VI secretion system (T6SS) in long-term gastrointestinal colonization.Scientific reports · 2022Article
- Peptidomimetics as Potential Anti-Virulence Drugs Against Resistant Bacterial Pathogens.Frontiers in microbiology · 2022Review
- Epidemiology and molecular characteristics of the type VI secretion system in Klebsiella pneumoniae isolated from bloodstream infections.Journal of clinical laboratory analysis · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe type VI secretion system (T6SS) has been identified as a novel virulence factor. This study aimed to investigate the prevalence of the T6SS genes in Klebsiella pneumoniae-induced bloodstream infections (BSIs). We also evaluated clinical and molecular characteristics of T6SS-positive K pneumoniae.
methodsA total of 344 non-repetitive K. pneumoniae bloodstream isolates and relevant clinical data were collected from January 2016 to January 2019. For all isolates, T6SS genes, capsular serotypes, and virulence genes were detected by polymerase chain reaction, and antimicrobial susceptibility was tested by VITEK® 2 Compact. MLST was being conducted for hypervirulent K. pneumoniae (HVKP).
results69 (20.1%) were identified as T6SS-positive K. pneumoniae among 344 isolates recovered from patients with BSIs. The rate of K1 capsular serotypes and ten virulence genes in T6SS-positive strains was higher than T6SS-negative strains (P = .000). The T6SS-positive rate was significantly higher than T6SS-negative rate among HVKP isolates. (P = .000). The T6SS-positive K. pneumoniae isolates were significantly more susceptible to cefoperazone-sulbactam, ampicillin-sulbactam, cefazolin, ceftriaxone, cefotan, aztreonam, ertapenem, amikacin, gentamicin, levofloxacin, and ciprofloxacin (P < 0.05). More strains isolated from the community and liver abscess were T6SS-positive K. pneumoniae (P < .05). Multivariate regression analysis indicated that community-acquired BSIs (OR 2.986), the carriage of wcaG (OR 10.579), iucA (OR 2.441), and p-rmpA (OR 7.438) virulence genes, and biliary diseases (OR 5.361) were independent risk factors for T6SS-positive K. pneumoniae-induced BSIs.
conclusionThe T6SS-positive K. pneumoniae was prevalent in individuals with BSIs. T6SS-positive K. pneumoniae strains seemed to be hypervirulent which revealed the potential pathogenicity of this emerging gene cluster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.